title: Treatment of primary intraocular lymphoma (PIOL) has involved systemic, intravitreal or intrathecal chemotherapy and/or radiotherapy.
authors.forename: Sujit
authors.initials: S
authors.lastname: Itty
authors.forename: Joshua H
authors.initials: JH
authors.lastname: Olson
authors.forename: Dennis J
authors.initials: DJ
authors.lastname: O'Connell
authors.forename: Jose S
authors.initials: JS
authors.lastname: Pulido
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage; D003131:Combined Modality Therapy / Q000379:methods; D005134:Eye Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007278:Injections, Spinal; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D008727:Methotrexate / Q000008:administration & dosage*; D008875:Middle Aged; D000069283:Rituximab; D014822:Vitreous Body
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D000069283:Rituximab; D008727:Methotrexate